IL273626B2 - Immunomodulatory fusion proteins - Google Patents

Immunomodulatory fusion proteins

Info

Publication number
IL273626B2
IL273626B2 IL273626A IL27362620A IL273626B2 IL 273626 B2 IL273626 B2 IL 273626B2 IL 273626 A IL273626 A IL 273626A IL 27362620 A IL27362620 A IL 27362620A IL 273626 B2 IL273626 B2 IL 273626B2
Authority
IL
Israel
Prior art keywords
cancer
fusion protein
seq
pharmaceutical composition
amino acid
Prior art date
Application number
IL273626A
Other languages
English (en)
Hebrew (he)
Other versions
IL273626A (en
IL273626B1 (en
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of IL273626A publication Critical patent/IL273626A/en
Publication of IL273626B1 publication Critical patent/IL273626B1/en
Publication of IL273626B2 publication Critical patent/IL273626B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
IL273626A 2017-09-27 2018-09-27 Immunomodulatory fusion proteins IL273626B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762564145P 2017-09-27 2017-09-27
PCT/US2018/053197 WO2019067770A1 (en) 2017-09-27 2018-09-27 IMMUNOMODULATORY FUSION PROTEINS

Publications (3)

Publication Number Publication Date
IL273626A IL273626A (en) 2020-05-31
IL273626B1 IL273626B1 (en) 2025-03-01
IL273626B2 true IL273626B2 (en) 2025-07-01

Family

ID=65902489

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273626A IL273626B2 (en) 2017-09-27 2018-09-27 Immunomodulatory fusion proteins

Country Status (13)

Country Link
US (2) US11834492B2 (enExample)
EP (1) EP3688037A4 (enExample)
JP (2) JP2020536518A (enExample)
KR (1) KR102757384B1 (enExample)
CN (2) CN111511769B (enExample)
AU (2) AU2018338612A1 (enExample)
BR (1) BR112020006115A2 (enExample)
CA (1) CA3077223A1 (enExample)
EA (1) EA202090838A1 (enExample)
IL (1) IL273626B2 (enExample)
MX (1) MX2020003672A (enExample)
SG (1) SG11202002826VA (enExample)
WO (1) WO2019067770A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519442A4 (en) 2016-09-27 2020-06-17 EpicentRx, Inc. Immunomodulatory fusion proteins
WO2021147886A1 (zh) * 2020-01-21 2021-07-29 张晋宇 一种药物组合物及其用途
CN113480662B (zh) * 2021-06-29 2022-07-22 北京双因生物科技有限公司 包含cd40抗体和il-15的融合蛋白及其制备方法和用途
CN116143946B (zh) * 2022-01-05 2025-12-09 赛德特生物制药有限公司 一种用于免疫治疗的新型融合蛋白、基因、重组载体、宿主细胞及应用
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途
WO2025221843A1 (en) * 2024-04-17 2025-10-23 Baylor College Of Medicine Methods and compositions for suppressing immune cell activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084337A1 (en) * 2005-02-14 2006-08-17 Apollo Life Sciences Limited A molecule and chimeric molecules thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1996011213A1 (en) 1994-10-07 1996-04-18 Amgen Boulder Inc. Dimeric il-4 inhibitors
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US5998598A (en) 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
TR199902878T2 (xx) 1997-04-18 2000-02-21 Biogen,Inc. Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
EP1087998A1 (en) 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
US20030125251A1 (en) 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
WO2003066002A2 (en) * 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
US20070184052A1 (en) 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
US20090111146A1 (en) 2003-09-02 2009-04-30 National Institute Of Advanced Industrial Science Antibody Drug
WO2006084327A1 (en) * 2005-02-09 2006-08-17 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
CN101146825A (zh) * 2005-02-14 2008-03-19 阿波罗生命科学有限公司 分子及其嵌合分子
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090175819A1 (en) * 2005-11-15 2009-07-09 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
EP3176264B1 (en) 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
WO2008157367A1 (en) 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
EP2293667A4 (en) * 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
EP2326670A4 (en) 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
PT2403951E (pt) 2009-03-02 2016-01-29 Univ California Mutantes de adenovírus e1a e e1b de tumores
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
EP4219536A3 (en) 2012-04-30 2023-08-23 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
PT2970512T (pt) 2013-03-12 2019-01-17 Biocon Ltd Proteínas de fusão imunomoduladoras e métodos para produção das mesmas
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
SG11201606577YA (en) 2014-02-10 2016-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
CA2979973A1 (en) * 2015-04-29 2016-11-03 Mediolanum Farmaceutici S.P.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
EP3344660B1 (en) 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
EP3519442A4 (en) 2016-09-27 2020-06-17 EpicentRx, Inc. Immunomodulatory fusion proteins
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084337A1 (en) * 2005-02-14 2006-08-17 Apollo Life Sciences Limited A molecule and chimeric molecules thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUMOUTIER LAURE ET AL,, CLONING OF A NEW TYPE II CYTOKINE RECEPTOR ACTIVATING SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT)1, STAT2 AND STAT3, 1 March 2003 (2003-03-01) *
KOTENKO S V ET AL,, IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A SECOND CHAIN OF THE INTERLEUKIN-10 RECEPTOR COMPLEX, 1 January 1997 (1997-01-01) *
LI, J. ET AL.,, TEMPORAL ASSOCIATIONS BETWEEN INTERLEUKIN 22 AND THE EXTRACELLULAR DOMAINS OF IL -22R AND IL -1 0R2, 1 May 2004 (2004-05-01) *

Also Published As

Publication number Publication date
CN111511769A (zh) 2020-08-07
US11834492B2 (en) 2023-12-05
CN118652350A (zh) 2024-09-17
JP2023096044A (ja) 2023-07-06
WO2019067770A1 (en) 2019-04-04
US20200223901A1 (en) 2020-07-16
EP3688037A4 (en) 2021-09-15
EP3688037A1 (en) 2020-08-05
CA3077223A1 (en) 2019-04-04
AU2018338612A1 (en) 2020-05-07
SG11202002826VA (en) 2020-04-29
US20240052016A1 (en) 2024-02-15
IL273626A (en) 2020-05-31
EA202090838A1 (ru) 2020-08-28
AU2025248681A1 (en) 2025-10-30
JP7702445B2 (ja) 2025-07-03
BR112020006115A2 (pt) 2020-11-17
KR102757384B1 (ko) 2025-01-20
IL273626B1 (en) 2025-03-01
KR20200057070A (ko) 2020-05-25
CN111511769B (zh) 2024-05-24
JP2020536518A (ja) 2020-12-17
MX2020003672A (es) 2020-08-03

Similar Documents

Publication Publication Date Title
IL273626B2 (en) Immunomodulatory fusion proteins
ES2704411T3 (es) Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas
KR102355950B1 (ko) Tigit에 대한 항체
JP2023096044A5 (enExample)
US20200362047A1 (en) Single domain antibodies that bind to cd137
HRP20240494T1 (hr) Kimerni antigenski receptori specifični za bcma i njihove upotrebe
CA3176246A1 (en) Antibodies to tigit
JP2020536518A5 (enExample)
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
TW201825511A (zh) 表現免疫檢查點調節子的溶瘤病毒
WO2019051126A4 (en) Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
WO2016191643A4 (en) Tigit-binding agents and uses thereof
US20200299412A1 (en) Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
WO2019090215A3 (en) Dominant negative ligand chimeric antigen receptor systems
CN116710556A (zh) 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备
US20180030124A1 (en) Methods and compositions for enhancing anti-ssea4 immunotherapy
US20190263886A1 (en) Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
JP2022544852A (ja) 抗原特異的ｔ細胞応答を活性化するための材料および方法
González-Navarro et al. What will (and should) be improved in CAR immunotherapy?
NZ767608B2 (en) Guidance and navigation control proteins and method of making and using thereof
JPWO2021218895A5 (enExample)
Calabrò et al. CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives
NZ767608A (en) Guidance and navigation control proteins and method of making and using thereof